4//SEC Filing
Gasmi Mehdi 4
Accession 0001209191-20-038635
CIK 0001501756other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 6:58 PM ET
Size
8.9 KB
Accession
0001209191-20-038635
Insider Transaction Report
Form 4
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
- Exercise/Conversion
Common Stock
2020-06-22$4.80/sh+23,605$113,304→ 298,047 total - Sale
Common Stock
2020-06-22$25.06/sh−23,605$591,617→ 274,442 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-06-22−23,605→ 83,000 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (23,605 underlying)
Footnotes (3)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $25.00 to $25.24. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Fully vested and exercisable.
Documents
Issuer
Adverum Biotechnologies, Inc.
CIK 0001501756
Entity typeother
Related Parties
1- filerCIK 0001614875
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 6:58 PM ET
- Size
- 8.9 KB